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SIMULTANEOUS COMPLEMENTARY IDIOTYPIC 
RESPONSES: ABSENCE OF RECIPROCAL REGULATION* 
BY DONALD  A. ROWLEY,  GARY  W. MILLER, AND INGRID LORBACH 
(From the La Rabida- University of  Chicago Institute, and the Department of  Pathology, University 
of Chicago, Chicago, Illinois 60649) 
A prior autogenous anti-idiotypic antibody response markedly suppressed the comple- 
mentary  idiotypic  response  and  vice  versa  (1). Interestingly,  neither  response  was 
diminished when mice were immunized to have simultaneous complementary responses. 
This apparent lack of reciprocal regulation is examined in the following experiments to 
determine whether a change in idiotypo of the complementary antibodies occurs and/or 
whether the antibodies produced simultaneously are capable of regulating the reciprocal 
responses. 
As in the previous study, the idiotypic and anti-idiotypic responses are those induced 
in A/He mice against phosphorylcholine (Pc) ~  and against a Pc-binding myeloma protein. 
Since antibodies raised against these antigens are directed, at least partially, against a 
combining site structure of the other, the antibodies are referred to as complementary 
idiotypos or antibodies  (1). Complementary idiotypes combine to quench or neutralize 
the activities of each other; thus, one complementary antibody can be used to inhibit 
hemolytic plaque formation by cells releasing the other antibody (2). The emergence of 
clones producing antibody of a different idiotype is revealed by the failure of a standard 
or "reference" complementary antibody to inhibit plaque formation by cells releasing the 
different  idiotype  (3-5).  Using  this  indicator,  we  find  no  evidence  in  the  present 
experiments that simultaneous complementary responses cause an early or rapid shift in 
idiotypes. 
Antibody  also  inhibits  immunization  and  clonal  expansion  of normal  cells 
producing the complementary antibody (6).  Presumably, antiserum from mice 
producing antibody of a different idiotype should be less effective in suppressing 
immunization.  Indeed, we report here that sera from mice immunized simulta- 
neously  to  have  circulating  levels  of both  complementary  antibodies  is  less 
effective  in  suppressing  plaque  formation  and  immunization;  however,  the 
ineffectiveness of such  sera  is apparently due  to the formation of complexes. 
The experimental findings suggest that the formation of circulating complexes 
is  a  result  rather  than  the  cause  of the  failure  of reciprocal  regulation  by 
complementary idiotypes. 
* Supported by U. S. Public  Health Service  grants  AI-I0242  and AI-9268,  by a grant from the 
Arthritis  Foundation,  and  by  a generous gift  from  the  Max Goldenberg Foundation. 
i  Abbreviations  used in this paper: ARA, anti-receptor  antibody  to  HS; FCA, Freund's  complete 
adjuvant;  FCS, fetal  calf  serum; FIA, Freund's  incomplete  adjuvant;  H8,  myeloma protein  HOPC- 
8; H8-SRBC, sheep erythrocytes  coated  with HS; HBSS, Hanks' balanced salt  solution;  MEM, 
minimum essential  medium; Pc, phosphorylcholine;  PcKLH, p-azophenylphosphorylcholine  con- 
jugated  to  keyhole  limpet  hemocyanin; Pc-SRBC, sheep  erythrocytes  coated  with  Pc;  PFC, plaque- 
forming cells;  SRBC, sheep  erythrocytes;  TNP, 2,4,6-trinitrophenyl(ated). 
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Materials and Methods 
M~e.  Mice were  A/He females 8-12 wk  old purchased from The Jackson Laboratory,  Bar 
Harbor,  Maine.  BALB/c  females  of the  same  age  purchased  from  Cumberland  View  Farms, 
Clinton, Tenn., provided cells for cultures. 
Antigens  and Immunizations.  A  formalin-killed vaccine of Diplococcus pneumoniae,  R36A, 
has Pc as a  major antigenic determinant which mice respond to; the antibody is predominantly 
IgM.  A  comparable  response to  Pc  is  induced by p-azophenylphosphorylcholine conjugated to 
keyhole limpet hemocyanin (PcKLH) (7). The same batches of vaccine and PcKLH were used in 
all  the  present  experiments.  Cultures  were  immunized  with  50  ~1  vaccine containing  ---- 107 
organisms. Mice were immunized with PcKLH; either 0.2 ml containing 0.7 mg PcKLH/ml saline 
given intravenously, or with 0.05 ml of a  mixture in adjuvants injected in a  hind foot pad. The 
mixture contained 1 part PcKLH 0.7 mg/ml,  1 part methylated bovine serum albumin 1 mg/ml, 
and  2  parts  Freund's  adjuvant.  Freund's  complete  adjuvant  (FCA)  was  used  for  the  first 
immunization; Freund's incomplete adjuvant (FIA) was used for subsequent immunizations. 
A  single batch of myeloma protein (HS),  produced by the plasmacytoma HOPC-8 in BALB/c 
mice and purified from ascitic fluid (8), was used in all experiments. The H8 protein is of the same 
idiotype as the TEPC-15  protein  (9).  We used H8  in the present experiments because we have 
been more successful in maintaining the HOPC-8 tumor in a stable form which produces abundant 
ascites containing large amounts of homogeneous protein.  For immunizations, one part HS,  1.2 
mg/ml, was homogenized with one part methylated bovine serum albumin and two parts Freund's 
adjuvant. FCA was used for the first immunization and FIA was used for subsequent immuniza- 
tions. Each immunization was in a depot of 0.05 ml in a hind foot pad. 
Antibody Titers.  Sera were assayed for antibody against Pc and H8 by agglutination of sheep 
erythrocytes coated with H8 (H8-SRBC) or  with C-polysaccharide extracted  from R36A (Pc-SRBC) 
as previously described (1).  Sera were assayed in duplicate against H8-SRBC, and SRBC; titers 
are recorded as the reciprocal,  log2,  of  the mean (to the nearest whole number) of  the highest 
serum dilution  which caused a dispersed pattern of  sedimentation of  target  erythrocytes.  Titers  to 
SRBC  were  always low or absent, and no attempt was made  to adjust titers  because of 
"background" antibody to  SRBC. 
Plaque-Forming Cells. The preparation  of spleen and lymph  node cells and assays  for 
numbers  of plaque-forming cells (PFC) to Pc-SRBC  and H8-SRBC  were done as previously 
described (1). Each suspension  of spleen or lymph  node cells  was assayed in triplicate  or 
quadruplicate for  PFC. Controls always included SRBC which were used alone as  target  antigen. 
The magnitude of  responses was calculated from counts using the target antigen minus counts 
against SRBC  (which rarely exceeded 1,000 PFC per spleen or 100 per lymph node). Additional 
controls in key experiments included: (a) cells  from mice immunized with Pc assayed against 
2,4,6-trinitrophenylated (TNP)-SRBC,  and  (b) cells from mice immunized  with TNP-Ficoll 
assayed against Pc-SRBC (1).  Cross-reactions,  either  stimulating or  inhibiting,  were not  detected 
and the  results  for  these controls  are  not  reported.  Specificity  controls  for  plaque formation to  H8- 
SRBC were not done in these experiments; in unpublished studies,  however, we found that cells 
from  mice  immunized  to the TEPC-15  myeloma  protein did not produce plaques  against 
erythrocytes coated with the IgA myeloma protein produced by the MOPC-315 tumor, and cells 
from mice immunized with the MOPC-315 protein did not produce plaques against erythrocytes 
coated with the  TEPC-15 protein. 
Inhibition of  Plaque Formation.  For inhibition of plaque formation, 50 ~l of serum diluted in 
Hanks'  balanced  salt  solution  (HBSS)  was  added  to  a  mixture of 0.3  ml  agarose,  50  ~l  of a 
suspension of lymphocytes,  and  50  ~tl of target cells just before the  mixture was  spread  and 
allowed to gel on glass slides, PFC to Pc-SRBC were counted after the slides were incubated at 
37°C for 1 h without complement and 1 h  with complement. Slides prepared with HS-SRBC were 
incubated with developing serum (1) 1 h before incubation with complement. Each serum dilution 
was  tested  in  triplicate or  quadruplicate  for each  cell  suspension assayed.  Controls  included 
normal serum, and in key experiments the sera were also tested for inhibition of plaque formation 
to TNP-SRBC by cells from mice immunized with TNP.  Again, data for these controls are not 
reported since the sera did not affect plaque formation by cells releasing anti-TNP antibody. 
Suppression of  Immunization  in Vitro.  Spleen cells were cultured in vitro using modifications 
of the Mishell-Dutton procedure  (2,  10);  1.5  ×  107 cells in 1.0 ml of minimum essential medium 
containing  10%  fetal  calf serum  (MEM-FCS)  were  cultured  in  35-ram  Falcon  culture  dishes 150  SIMULTANEOUS COMPLEMENTARY IDIOTYPIC RESPONSES 
(Falcon  Plastics,  Div.  of  BioQuest, Oxnard, Calif.).  Sera  or  other materials  tested  in  culture  were 
diluted in MEM-FCS  and sterilized  by filtration  (Millex 0.45-~m disposable filter  units). 
Additional dilutions  were than made in MEM-FCS. Usually, 50 ~l of  each  dilution  was added to 
each of  three or four  cultures  I h before  cultures  were immunized with 50 pl of  R36A vaccine.  4 
days later  the cells  were harvested, washed twice in 3.0 ml HBSS, and resuspended in 1.0 ml 
HBSS. Each culture  was  assayed  for  PFC in  duplicate  or  triplicate,  using  100  ~l  of  cell  suspension 
per slide.  The magnitude of  responses of  normal A/He spleen cells  to immunization with Pc is 
usually ~ 20% of  that obtained with BALB/c cells.  For this  reason, except as noted in the text, 
BALB/c spleen  cells  were used  for  cultures. 
Antiserum to  H8.  A single  pool  of  "reference"  antiserum to  the H8 idiotype  was raised  in  60 
A/He mice  each  injected  six  times  at  weekly intervals  with 0.2  ml of  H8 in  adjuvants prepared  as 
described above; mice were bled 10 days after the final  immunization. The serum had an 
agglutinin titer  of 13 to H8-SRBC. For convenience, this  pool  is referred  to as anti-receptor 
antibody  (ARA) since  the antibody can be considered as directed against a combining site 
structure  for  Pc (though  it  would  be  just  as  logical  to  refer  to  the  anti-Pc  antibody as  anti  receptor 
antibody since  it  functions  as  an antibody directed  against  the  complementary receptor). 
Serum Anti-Pc Ig.  Normal BALB/c serum from adult  mice  contains  antibody to Pc  of  the T15 
idiotype (11);  to isolate  this  naturally occurring idiotype,  serum was precipitated  with 45% 
saturated ammonium sulfate.  The precipitate  dissolved  in  distilled  water  was passed through an 
Ultrogel AcA-34 column (LKB Produkter, Stockholm, Sweden) to obtain an Ig fraction  of 
150,000  daltons.  The amount of  H8 idiotype  present in the Ig fraction  was determined by inhi- 
bition  of binding of radiolabeled  H8 to ARA  in a solid-phase  radioimmunoassay (12).  This Ig 
fraction  was added to cultures  to reverse suppression by ARA  (Table VIII). 
Calculations and Recording of  Data.  The number of  PFC per slide  usually varies  twofold  or 
less  when multiple slides  are prepared from a single  suspension of  cells  (lymph node, spleen,  or 
culture).  When results  are  for  pools  of  cells  (Tables  II,  Ill,  VI, VII),  the  arithmetic  mean of  counts 
on  three  or  more replicate  slides  is  reported.  The variability  of  individual  responses (measured  by 
counting plaques  on replicate  slides  for  each individual)  is  a direct  function  of  the magnitude of 
responses.  For reasons previously  discussed (13),  the means of  groups of  identically  treated  mice 
or  cultures  are  calculated  on  log-transformed  data.  Thus, the  number of  PFCs recorded  for  groups 
of  similarly  treated  mice or  cultures  (Tables I, IV, V, VIII,  and in  the text)  is  the antilog  of  the 
mean for  the  group;  the  log  of  the mean _+ the standard  error  is  given  in  parentheses. 
Results 
Preliminary  Observations.  Prior  immunization  with  TEPC-15  myeloma 
protein markedly suppressed subsequent immunization  with Pc and vice versa 
(1). These observations were repeated to establish that comparable results were 
obtained using the present reagents.  Five mice were immunized three times at 
weekly  intervals  with  H8  in  adjuvants,  and  five  mice  were  injected  with 
adjuvants  only.  1 week after the  third  injection,  these and five normal  mice 
were challenged  intravenously  with  both  Pc-KLH and  TNP-Ficoll; responses 
were measured  4  days later.  Mice preimmunized  with  H8 had  1,050  (3.02  _+ 
0.12) PFC, whereas the control groups had 20,500  (4.31  _+ 0.26) and 18,400  (4.25 
_+ 0.32) PFC to Pc-SRBC per spleen. The three groups had comparable responses 
to TNP with 45,000 (4.65  _+ 0.32),  56,000 (4.74 _  0.41), and 39,000 (4.59 __+ 0.28) 
PFC/spleen respectively. In a reciprocal experiment, mice were immunized once 
a  week  intravenously  with  Pc-KLH.  Beginning  1  wk  after  one  to  three 
immunizations  with  Pc-KLH,  foot pads  were injected  with  H8  in  adjuvants; 
popliteal  lymph  nodes  were  assayed  for  PFC  4  days  ai~r  two  injections. 
Preimmunization  with Pc beginning  1 wk before immunization  with H8 very 
effectively suppressed the response to  HS:  responses were 1,800  (3.25  -_-  0.64) 
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similar when challenge with H8 was begun after two or three immunizations 
with Pc. 2 
The ARA raised in A/He mice against H8 effectively suppressed immuniza- 
tion to Pc in both A/He and  BALB/c mice.  For example,  0.2 ml of ARA was 
given intraperitoneally to each of four normal adult BALB/c mice, and to each 
of four normal A/He mice 24 h  before i.v. immunization  with 0.2 ml Pc-KLH. 
Four  control  BALB/c  and  4  A/He  mice  received  Pc-KLH  only.  Mean  PFC 
responses per  spleen 4 days later  were:  <1,000  (2.90  +-  0.11) for treated  and 
78,600  (4.89  _+  0.07)  for  control  BALB/c  mice,  and  <1,000  (2.74  +_  0.20)  for 
treated  and 18,500  (4.26  _+  0.24) for control A/He mice.  Also, ARA effectively 
suppressed  immunization  to  Pc  in  vitro  after  absorption  on  BALB/c  serum 
(previously absorbed with Pc-Sepharose to eliminate the Pc idiotype), but not 
aider absorption with serum from BALB/c mice hyperimmunized to Pc, Table I. 
Taken  together,  the  findings  indicate  that  suppression  by  ARA  is  due  to 
antibody directed against a  Pc binding site structure. 
Whereas  prior  immunization  with  either  Pc  or  H8  markedly  suppressed 
immunization to the other antigen,  this was not the case when immunizations 
with the two antigens  were begun simultaneously.  This was found to be the 
case whether the conditions  of immunization  were adjusted to give compara- 
tively low or high responses to either antigen. 
Low Anti-Pc Responses  Occurring  Simultaneously  with High Anti-H8 Re- 
sponses.- The conditions for this set of experiments were purposely selected to 
give a  high  anti-H8 and a  low anti-Pc response.  This was done with the idea 
that  these  conditions  would  provide  "maximum  selective pressure"  favoring 
emergence of new anti-Pc idiotypes. A low but reproducible response to Pc was 
obtained when mice were immunized in one third foot pad with the Pc-KLH in 
adjuvants. 4 days after two to six weekly immunizations,  the draining popliteal 
lymph node contained 400-2,000 PFC to Pc-SRBC; sera from such mice had no 
detectable  agglutinins  for  Pc-SRBC.  Mice immunized  identically  with  H8 in 
adjuvants three or more times had 10,000-50,000 PFC to HS-SRBC per draining 
popliteal lymph node, and sera from such mice had agglutinin titers of 7-12 for 
H8-SRBC. Neither antigen induced a measurable response in the contralateral 
node, and neither antigen induced a  measurable response to the other antigen 
in either node.  These immunization  procedures were then used in a  series of 
experiments of the same basic design: one group was immunized in one foot pad 
with H8 only, a  second group was immunized  in the opposite foot pad with Pc 
only, and a third group was immunized with H8 in one foot pad and with Pc in 
the other foot pad.  Immunizations  were repeated every 7 days and responses 
2  It  was previously shown (1)  that large amounts of  soluble  TEPC-15 myeloma protein injected 
into  mice at the time of  immunization with Pc did not suppress immunization to Pc. Similarly, 
large  "paralyzing" doses of  Pc-containing C-polysaccharide given I  or 7 days before  immunization 
with TEPC-15 did not suppress immunization to TEPC-15. Thus, it is very unlikely that sup- 
pression produced by prior  immunization was due to residual free  antigen which combined with 
and  neutralized  the  second  antigen. Also,  antibody  to  Pc  given  passively  suppressed immunization 
with TEPC-15, and antibody against TEPC-15 given passively suppressed immunization to Pc. 
Together  these  results support  the contention  that  prior immunization  with one antigen 
suppresses  subsequent immunization  with the other antigen  because of an active immune 
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TABLE  I 
Suppression of Immunization to Pc by ARA Is Due to Antibody Directed against the 
A nti-Pc Idiotype 
Dilution of  PFC to Pc-SRBC per  cul- 
Exp.  Added to  cultures* 
ARA  ture$ 
1  ARA  1:40  87 (1.94  -+ 0.20) 
ARA  absorbed*  1:40  51 (1.71  - 0.25) 
ARA  1:200  478 (2.68  ± 0.15) 
ARA  absorbed*  1:200  776 (2.89  ± 0.10) 
Medium  -  1,380 (3.14 -+ 0.09) 
ARA  1:40  138  (2.14 ±  0.09) 
ARA reabsorbed on MOPC-47A§  1:40  208  (2.32  -+ 0.18) 
ARA reabsorbed on anti Pc serum§  1:40  1,621  (3.21  ±  0.09) 
Medium  -  1,862  (3.27  -+ 0.05) 
* ARA diluted 1:40 in buffered  saline was absorbed exhaustively  on a column  of normal BALB/c 
serum  coupled to  Sepharose; the  BALB/c serum  had  been  previously  absorbed  with  Pc-Sepharose 
to  eliminate the Pc  idiotype;  50/~l  was added  to  each  culture. 
All  cultures  were immunized with R36A vaccine and assayed  4  days  later.  PFC to  Pc-SRBC per 
culture  were calculated  from  counts on  nine  slides  prepared  in  triplicate  from  three  cultures. 
§  Aliquots of absorbed serum, exp: I, were reabsorbed  on pooled serum from BALB/c mice 
hyperimmunized to Pc or on a non-Pc binding IgA myeloma protein,  MOPC-47A, coupled to 
Sepharose. 
were measured 4 days after three to six immunizations. The results of a typical 
experiment using cells and sera pooled from groups of five mice are reported in 
Tables II-IV. The mean responses to Pc and H8 were equivalent whether mice 
were immunized with one or both antigens; sera from the groups immunized 
with H8 had high antibody titers to HS, but sera from groups immunize with Pc 
had no detectable antibody to Pc  (Table II).  Plaque formation to Pc-SRBC by 
cells  from  mice  immunized  with  Pc  only  (group  2),  or  by  cells  from  the 
appropriate  nodes of mice  immunized with both  Pc  and  H8  (group  3),  was 
equally inhibited by ARA or by serum from mice immunized with H8  only 
(group 1),  or by serum from mice immunized with both Pc and H8  (group 3, 
Table III). Also, the pooled sera from mice immunized with H8 only or serum 
from mice immunized with both antigens produced equivalent suppression of 
immunization in  vitro  (Table  IV).  Results  comparable  to  those  reported  in 
Tables II-IV were obtained in two other experiments of the same design, and 
also in two experiments in which pools of cells and sera were obtained from 
mice after four or six immunizations. 
The experiments did not rule out the possibility that individual mice produced 
different anti-H8 and anti-Pc idiotypes. If this had been the case, then pooled 
serum could inhibit plaque  formation by cells producing anti-Pc antibody of 
non-H8 idiotype. Therefore, experiments were designed to test whether lymph 
node cells from individual mice immunized to both Pc and H8 were susceptible 
to suppression by their own anti-H8 antibody, as were cells from individual 
mice immunized with Pc only. Because the responses to Pc were low, it was not 
possible to prepare more than 10 slides using cells obtained from an immunized 
lymph node of a  single mouse and still have reasonable numbers of PFC per 
slide.  Working with  this  restriction,  sera  and  cells  from  the  lymph nodes DONALD  A.  ROWLEY,  GARY  W.  MILLER~  AND  INGRID  LORBACH 
TABLE  H 
Complementary Responses  in Popliteal Lymph Nodes 
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Response to H85  Response to Pc$ 
Group*  Immunization 
PFC per  Serum an-  PFC per  Serum an- 
lymph node  tibody titer  lymph node  tibody titer 
1  H8  16,500  9  -  0 
2  Pc  -  0  1,040  0 
3  H8 and Pc  14,450  8  1,440  0 
* Groups of five mice were immunized three times at weekly intervals: group 1 in the right hind 
foot pad with H8, group 2 in the left hind foot pad with Pc-KLH, and group 3 in the right hind 
foot pad with H8 and the left hind foot pad with Pc-KLH. Both antigens were in adjuvants. 
$ Mice were sacrificed 4 days after the third immunization. The results are for pools of cells 
assayed in triplicate or sera assayed in duplicate. 
TABLE  III 
Inhibition of  Plaque Formation by Sera from Mice Immunized with H8 or with Both 
H8 and Pc Using Lymph Node Cells Immunized to Pc 
Sera* 
Lymph node cells immunized to Pc 
from mice in:* 
Group 3 (immu- 
Group 2 (immu-  nized with Pc and 
nized with Pc)  H8) 
Source  Dilution  PFC per  sup-  PFC per  Sup- 
slide  pres-  slide  pres- 
sion  sion 
Group 1 (Immunized with HS) 
Group 3 (Immunized with H8 and Pc) 
ARA 
N.S. 
None 
%  % 
1:10  10  90  48  67 
1:100  17  84  40  73 
1:1,000  68  35  88  39 
1:10  2  98  0  100 
1:100  30  71  64  56 
1:1,000  96  8  104  28 
1:500  51  49  75  52 
1:10  93  11  124  14 
104  0  144  0 
* The sera and lymph node cells  are the pools  from the groups reported 
are means for  counts on three or four  slides. 
N.S., normal A/He serum. 
in Table II. PFCs per slide 
immunized  to Pc were obtained from each of four mice immunized  three times 
with both H8 and Pc,  and from each of four mice immunized  three  times with 
Pc only. The serum  from one mouse immunized  with both antigens  was tested 
for inhibition of plaque  formation  by cells from  that  mouse  and  by cells from 
one  mouse  immunized  with  Pc  only.  Each  lymph  node  cell  suspension  was 
assayed  against  Pc-SRBC  in  triplicate with  each  of three  sera:  (a)  the  donor 
serum diluted 1:100,  (b) ARA diluted 1:500, and (c) normal serum diluted 1:100. 
Each donor serum  and ARA produced 57-85%  inhibition and, in each instance, 
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TABLE  IV 
Suppression of  Immunization to Pc in Vitro by Sera from Mice Immunized with H8 
Alone or with Both H8 and Pc 
Sera from:*  Dilution 
Suppression of immunization to Pc$ 
Mean PFC per culture 
Sup- 
pres- 
sion 
Group 1 (immunized with H8) 
Group 3 (immunized with Pc and H8) 
ARA 
N.S.§ 
Medium 
% 
1:5  301  (2.48  -+ 0.22)  63 
1:25  437 (2.64  -+ 0.20)  52 
1:125  794 (2.90  ± 0.16)  13 
1:5  257 (2.41  ±  0.31)  72 
1:25  347  (2.54 +  0.05)  62 
1:125  691  (2.84  ±  0.10)  24 
1:500  269 (2.43  ±  0.11)  71 
1:5  1,071 (3.03  ±  0.06)  - 
912 (2.96  ±  0.04)  0 
* The sera are pools obtained from the groups, Table I; 50 ~l of a dilution of serum was added to 
each of 4 cultures. 
Each culture was immunized with R36A vaccine after addition of serum or medium. PFC per 
culture were calculated from counts on nine slides prepared in triplicate from three cultures. 
§ N.S., normal A/He serum. 
cells came from the serum donor or from a  mouse immunized to Pc only. This 
finding was confirmed in two more experiments of similar design. 
Thus,  with simultaneous  immunizations  the anti-Pc PFC response was not 
affected  even  though:  (a)  plaque  formation  by  the  cells  releasing  anti-Pc 
antibody was demonstrably inhibitable by anti-idiotypic antibody, and (b) large 
amounts  of such  antibody,  capable  of both  inhibiting  plaque  formation  and 
suppressing immunization in vitro, were present in the serum. 
"High" Anti-Pc Responses Occurring Simultaneously  with High Anti-H8 
Responses.-The above experiments should have been optimal for demonstrat- 
ing new anti-Pc idiotypes if they emerged within the first weeks of simultaneous 
responses; it remained possible, however, that high anti-Pc as well as high anti- 
H8 responses  might  be  more  favorable for the  appearance  of new  idiotypes. 
Therefore,  experiments  of the same design as described above were repeated, 
except that mice were immunized to Pc by injecting them intavenously with Pc- 
KLH in saline.  With this route and form of antigen,  PFC responses to Pc were 
higher,  and serum contained  antibody to Pc. Again,  simultaneous  immuniza- 
tion with H8 did not diminish the PFC response to Pc, though serum antibody 
levels to  Pc were reduced  significantly  (Table  V).  ARA produced  equivalent 
inhibition  of plaque  formation  whether  spleen cells were obtained from mice 
immunized with one or both antigens  (Table VI). However, pooled serum from 
mice  immunized  with  both  antigens  was  relatively  ineffective  in  inhibiting 
plaque formation to Pc-SRBC using cells from mice immunized  to Pc (exp.  1, 
Table VII). 
Results comparable to those reported in Tables V  and  VI were obtained in 
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Group*  Immunization 
Responses to H85 
PFC per lymph node 
Response to Pc~ 
Serum 
Serum anti-  anti- 
body titer  PFC per spleen  body ti- 
ter 
1  H8  19,500 (4.29 ± 0.23)  10 (10-12)  -  0 
2  Pc  -  0  5,250 (3.72 ± 0.32)  7 (5-8) 
3  H8 and Pc  25,700  (4.38 ± 0.19)  10  (9-11)  3,390(3.54  ± 0.32)  3 (1-4) 
* Groups of five mice were immunized three times at weekly intervals: group 1 in hind foot pads 
with H8,  group 2 intravenously with Pc-KLH,  and group 3 in hind foot pads with H8 and 
intravenously  with Pc-KLH. 
Mice were sacrificed  4 days after the third immunization. Results were calculated from the 
individual PFC and antibody responses of mice. Differences between groups for PFC responses 
to Pc and H8, and antibody responses to H8 were not significant; differences between groups for 
antibody responses to Pc are significant,  P  =  <0.01. 
TABLE  VI 
Plaque Formation Was Equally Inhibited by ARA Whether Cells 
Were from Mice Immunized with PC Only or from Mice Immunized 
with Both Pc and H8 
Group 2 spleen cells* 
(mice immunized with Pc) 
Group 3 spleen cells* 
(mice immunized with Pc and H8) 
PFC per slide  PFC per slide 
N.S.  ARA  Suppression  N.S.  ARA  Suppression 
1:100§  1:500  1:100  1:500 
%  % 
286  197  31  117  59  50 
182  46  49  89  85  5 
144  74  75  50  14  72 
49  26  47  46  19  59 
32  15  53  21  9  57 
Mean = 51  Mean = 49 
* Spleen cells  were obtained from the individual mice, groups 2 and 3, Table 
V. The number of PFC  per slide is the mean for counts on four slides 
prepared from an individual mouse. 
§ N.S.,  normal A/He serum. 
immunized with both antigens were relatively ineffective in inhibiting plaque 
formation to  Pc-SRBC  (exp.  2-4,  Table  VII).  Sera  which were  ineffective for 
inhibiting plaque formation were also ineffective in suppressing immunization 
to Pc.  For example, 50/~1 of dilutions of the pooled sera from groups of mice in 
experiments  1  and  4,  Table  VII,  were  added  to  cultures  of normal  BALB/c 
spleen cells 1 h  before immunization to Pc. Group 1 sera (immunized to H8 only) 
from both experiments diluted 1:100 caused >80% suppression, whereas group 3 
sera (immunized to both Pc and HS) from both experiments diluted 1:10 or 1:25 156  SIMULTANEOUS  COMPLEMENTARY  IDIOTYPIC  RESPONSES 
TABLE  VII 
Failure of Sera from Mice Immunized with Both H8 and Pc to Inhibit 
Plaque Formation to Pc-SRBC 
Exp. 
Mean number of  PFC to  Pc-SRBC/slide*  Suppression 
Group 1 serum  Group 3 serum 
N.S.§  hl00  1:100  Group 3 se- 
1:100  (immunized to  (immunized to  Group 1 serum*  rum* 
H8)  Pc and H8) 
% 
1  72  15  65  79  10 
2  85  35  80  58  6 
3  24  6  24  75  0 
4  180  38  165  79  8 
Mean = 73  6 
* The spleen cells were pools. For exp.  1, the cells and sera were pooled from the 
individual  mice reported in Table IV. Experiments 2, 3, and 4 were identical to 
exp. 1. In each experiment, pooled sera were tested using pooled group 2 spleen 
cells obtained in that particular experiment. The number of PFC per slide is the 
mean for counts on three slides. The difference in suppression produced by group 1 
and 3 sera in the four experiments is significant (P < 0.01). 
N.S., normal A/He serum. 
caused >80% suppression,  and diluted  1:100 caused  <10% suppression.  (The P 
value for differences between responses of cultures treated with group 1 and 3 
sera diluted 1:100  was <0.01 in both experiments.) 
The relative ineffectiveness of sera from mice immunized with both antigens 
to suppress  might be due to some qualitative  change  in  antibody released  by 
cells  immunized  to  H8.  This  possibility  was  tested  by  using  antisera  to  Pc 
obtained in experiments 3 and 4, Table VII, to inhibit plaque formation by cells 
immunized to H8; thus,  50 gl of either normal serum or the group 2 serum (i.e. 
immunized to Pc) diluted 1:500,  1:2,500, or 1:12,500 was added per slide of lymph 
node  cells  assayed  against  H8-SRBC.  Each  serum  dilution  was  tested  in 
triplicate  and  the  percent  inhibition  was calculated  from the  counts obtained 
with normal serum diluted 1:500. In experiment 3, group 2 serum diluted 1:2,500 
inhibited  plaque  formation of group  1  lymph node  cells by  78%  and  group  3 
lymph node cells by 74%. In experiment 4, group 2 sera diluted 1:2,500 inhibited 
plaque formation of group 1 lymph node cells by 41% and group 3 lymph node 
cells by 43%.  In both experiments,  dilutions  of 1:500  caused  >90%  inhibition 
and dilutions of h12,500 caused <10% inhibition.  Thus, insofar as it was tested, 
plaque formation by cells releasing anti-H8 antibodies was equally inhibited by 
anti-Pc  antibody  whether  cells were  obtained  from mice immunized  with  H8 
only, or from mice immunized with both H8 and Pc. 
In these  experiments antibody released by cells in  vitro was not  detectably 
different whether cells came from mice immunized with one, the other, or both 
antigens, though serum from mice immunized with both antigens was relatively 
ineffective in inhibiting plaque formation and suppressing immunization to Pc. 
This latter finding could be due to the formation of complexes of the complemen- 
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mice immunized to both antigens, Table V, was compatible with this possibility, 
and the following observations add support to it. 
Complexes in Sera from Mice Immunized with Both Antigens.- Sera having 
antibody activity against both Pc and H8 should contain complexes of the two 
antibodies. The existence of such complexes was indicated in the following way. 
Putative  complexes were formed by mixing  ARA diluted  1:20 with  an  equal 
volume of antisera from A/He mice immunized three times with R36A vaccine. 
The diluted ARA had a titer of 8 to H8 and the antiserum to Pc had a titer of 6 
to Pc; after incubation overnight at 4°C, the mixture had a titer of 8 to H8 and 5 
to Pc. Thus, the mixture retained both antibody activities. Aliquots of the origi- 
nal 2 sera and of the mixture containing putative complexes were each absorbed 
with  an  equal  volume  of packed  Pc-SRBC  or  H8-SRBC for  30  min  at  4°C. 
Absorption of the  mixture  with  H8 reduced  the  titer  to Pc from 5 to  3,  and 
absorption with Pc reduced the titer to H8 from 8 to 4. Titers of the two origi- 
nal  sera  were reduced  only by absorption  with the  antigen  that  the  antise- 
rum was directed against.  Also,  the pooled sera from the groups reported in 
Table V  were absorbed in the  same way with either  Pc or H8,  and  then ti- 
tered against the two antigens.  The absorption of group 3 serum (mice immu- 
nized  with  both  Pc  and  HS)  with  either  Pc-SRBC  or  H8-SRBC  eliminated 
the titer to Pc and reduced the titer to H8 from 11 to 8, whereas titers of group 
1 and 2 sera were only reduced by absorption with the antigen with which the 
donor mice were immunized.  Thus, the effects of the absorptions on titers were 
equivalent whether appropriate sera were mixed in vitro to form complexes, or 
whether sera came from mice immunized  with both antigens.  These findings 
suggested that complexes, presumably in equilibrium with free antibody, retain 
some available combining sites so that absorption with either antigen removed 
both antibodies. 
Partial Reversal of Suppression  by Antibody to Pc.  Apparently,  when mice 
are simultaneously immunized to have high levels of complementary antibod- 
ies,  complexes form which are  ineffective immunosuppressants.  If this  is the 
case,  then  antibody  to  Pc  should  prevent  suppression  by ARA.  To  test  this 
possibility, purified H8 protein or an Ig fraction of serum containing antibody to 
Pc was added to cultures just before addition of ARA and R36A vaccine. The Ig 
fraction  rather  than  whole  serum  was  used  because  whole  serum  free  of 
antibody to Pc contains factors which enhance the response of cultures to Pc. 
PFC responses were measured 4 days later.  The highest  concentration  of H8 
tested caused suppression, and this quantity of H8 was ineffective in reversing 
suppression; quantities of H8 or the Ig fraction,  however, which alone neither 
enhanced nor suppressed significantly, partially prevented suppression by ARA 
(Table VIII).  The serum Ig fraction was tested in a  series of experiments  at a 
single  concentration  of 266  ng  of idiotype per  culture.  Suppression  of >90% 
produced  by  ARA  was  reduced  to  <50%  in  all  experiments.  In  addition, 
absorption of the fraction with Pc coupled to Sepharose eliminated the capacity 
of the fraction to partially reverse suppression by ARA. 
Discussion 
Complementary  responses  induced  simultaneously  in  adult  mice  did  not 
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TABLE  VIII 
Partial Reversal of Suppression by Antibody to Pc 
Nanograms/  Suppres- 
Exp.  Idiotype  culture*  ARA*  PFC to Pc-SRBC per culture§  sion 
% 
H8 
H8 
0  0  1,348 (3.13 -  0.09) 
200  0  977 (2.99 _ 0.07)  17 
40  0  1,445 (3.16 -+ 0.04)  0 
8  0  1,318 (3.12 -- 0.07)  2 
0  +  204 (2.31 -- 0.13)  85 
200  +  380 (2.58 -  0.09)p =  <0.01  72 
40  +  1,047 (3.02 ± 0.07)--  22 
8  +  263 (2.42 _ 0.16)  80 
Serum  0  0  1,778 (3.25 _  0.09) 
Ig  800  0  1,549 (3.19 -- 0.07)  13 
266  0  1,738 (3.24 ± 0.03)  2 
89  0  1,738 (3.24 _+ 0.07)  2 
Serum  0  +  309 (2.49 _+ 0.15)  83 
Ig  800  +  1,047 (3.02 ±  _  0.08)p =  <0.01  41 
266  +  955 (2.98 + 0.10)--  46 
89  +  646 (2.81 _+ 0.06)  64 
* In exp.  1, 50/~1  of culture medium alone or the same volume containing purified H8 in the 
amount indicated was added to each of three or four cultures. In exp. 2, 200/~l of phosphate- 
buffered saline alone or the same volume containing the Ig fraction in the amount indicated was 
added to each culture. 
* Either 50 pJ of culture medium alone or the same volume of ARA (absorbed) diluted 1:100 in 
culture medium was added to each culture. 
§ All cultures were immunized with R36A vaccine; each culture was assayed in triplicate 4 days 
later. In exp. 1, the P value is for the difference between cultures with ARA but no idiotype and 
cultures with ARA and 40 ng of idiotype per culture. In exp. 2, the P  value is for the difference 
between cultures with ARA but no idiotype and cultures with ARA and either 800 or 266 ng of 
idiotype per culture. 
conclusion at least can be drawn  using the same procedure which demonstrated 
emergence  of  different  idiotypes  in  neonatally  suppressed  mice  (4,  5),  i.e., 
inhibition  of  plaque  formation  by  complementary  idiotype.  Of  course,  the 
effectiveness for resolving different idiotypes using anti-idiotypic antibody must 
be a  function of the homogeneity  of idiotypes used for inhibition. Though  A/He 
mice have  the  repertoire to produce various anti-Pc idiotypes, the response of 
normal  adults is predominantly  of the H8 (T15) idiotype (14,  15).  Less is known 
about  the  heterogeneity  of  anti-idiotype  antibodies  raised  against  myeloma 
proteins, though  purified A/He antibody to H8, prepared  from the same pool as 
used  in  these  studies,  is of highly  restricted  class and  spectrotype  (16),  as  is 
BALB/c  antibody  raised  against  MOPC-168  myeloma  protein  (17).  Also,  the 
observation that antisera to each antigen caused equivalent inhibition of plaque 
formation by cells immunized  to produce the complementary  antibody suggests 
that both responses are of similar heterogeneity. It seems reasonable to assume, 
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detected such changes by measuring inhibition of plaque formation by cells 
from mice immunized to  have simultaneous complementary responses.  This 
assumption is further supported by demonstrating that sera from individual 
mice  immunized  with  both  antigens  (but  to  have  a  low  response  to  Pc) 
suppressed plaque formation by the individual's own lymph node cells immu- 
nized to Pc. 
It  is  true  that  serum  from  mice  immunized to  have  high  simultaneous 
responses was relatively ineffective in  inhibiting plaque formation and sup- 
pressing immunization to Pc; this finding might be interpreted as evidence for 
a change in idiotype of anti-H8 antibody. However, plaque formation by lymph 
node cells  immunized to  H8  from  these  mice was  "normally" inhibited  by 
antibody to Pc, and sera from such mice contained immune complexes. In all 
probability, antibody to Pc neutralized or quenched the activity of antibody to 
H8 in these sera. 
Mice immunized to have low responses to Pc had no measurable agglutinins 
to Pc;  sera from mice immunized in this way to Pc and also to H8  were as 
effective as  sera  from  mice  immunized only  with  H8  in  inhibiting  plaque 
formation and suppressing immunization to Pc.  Thus, in mice immunized to 
have simultaneous low responses to Pc and high responses to Ha, the absence of 
reciprocal regulation cannot be accounted for by the formation of complexes, at 
least by appreciable levels of circulating complexes. Presumably, the mecha- 
nisms preventing reciprocal regulation are the same whether mice had low or 
high  responses to  Pc.  If this  is  the  case,  then the  formation of circulating 
complexes in mice immunized to have high responses to both Pc and H8 is a 
result rather than the cause for the absence of reciprocal regulation. 
Complementary responses  induced  simultaneously coexist  apparently  be- 
cause of the continued absence of reciprocal regulation of the original dominant 
B-cell  clones. Initially, the stimulated clones must proliferate and synthesize 
antibody in the absence of appreciable complementary idiotype. With progres- 
sion of responses, released antibody (which can be considered as shed antigen) 
may shield cells from being targets for complementary  idiotype, and in this way 
prevent regulation. For example, ARA given to mice or added to cultures more 
than 1 day after immunization with Pc fails to suppress the continued prolifer- 
ation of cells releasing antibody to Pc (6). However, ARA will suppress if the 
cells from the mice or cultures are washed thoroughly (D. A. Rowley, unpub- 
lished observations), presumably because free anti-Pc antibody is removed. But 
other mechanisms are probably involved at later stages after immunization. 
For example, we have found that (FAB)~ fragments prepared from ARA (which 
retain full combining activity with the H8 idiotype) do not suppress immuniza- 
tion to Pc in vitro (12). This suggests that cross-linking of surface Fc and Ig 
receptors may be required for suppression. Responding cells may differentiate 
and  mature to  stages which are not as susceptible to  regulation because of 
change in density or distribution of Fc or Ig receptors, or because of loss  of 
interaction between these receptors (18-21). Alternatively, it is possible that 
complexes of antigen-antibody or  antibody-antibody formed on  or  near the 
surface membrane of responding cells binds to Fe receptors to prevent regulation 
by free complementary antibody. 
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possible that the absence of reciprocal regulation may be a result of a change 
affecting either regulatory cells and/or the susceptibility of responding B cells 
to regulatory cells.  But once a  response develops beyond some critical stage 
beginning about  24  h  after immunization, specific  suppression  mediated by 
complementary antibody or suppressor cells is apparently much less effective. 
Presumably,  this  occurs  so  that  an  ongoing  or  secondary response  is  not 
prematurely or  inappropriately turned  off. Thus,  the  absence  of reciprocal 
regulation in the present model may be a manifestation of a usual maturation 
process. 
Though simultaneous complementary responses were induced intentionally 
and quite artifically in these experiments, the potential may exist in nature for 
other antigens and antibodies to stimulate comparable responses. Antibodies or 
antigen-antibody complexes can induce anti-idiotypic responses, and the infer- 
ence is that complexes formed in vivo may account for induction of autogenous 
anti-idiotypic antibodies  (22-31). Also,  preliminary studies in our laboratory 
suggest that some complex antigens may contain complementary  determinants, 
each of which stimulates directly one of the complementary antibody responses 
(D. A. Rowley, unpublished observations). But regardless of the mechanisms, 
simultaneous complementary  responses may cause untoward effects, e.g., tissue 
deposition  of complexes  and  activation  of complement components.  These 
possibilities are being investigated in our laboratory. 
Summary 
Complementary antibodies, i.e. antibodies having combining site structures 
which are at least partially directed against each other, were induced in A/He 
mice by immunization with phosphorylcholine (Pc) coupled to keyhole limpet 
hemocyanin or with the Pc-binding IgA myeloma protein, HOPC-8  (H8). Both 
responses were monitored by enumerating plaque-forming cells and assaying 
serum antibody levels to Pc and H8.  Prior immunization with H8  markedly 
suppressed subsequent immunization with Pc and vice versa; neither plaque- 
forming cell response was diminished, however, when mice were immunized 
simultaneously with Pc and H8. 
Experiments were designed to determine if the absence of reciprocal regula- 
tion  was  due  to  change  in  idiotypes.  This  was  determined by  measuring 
inhibition of plaque formation using complementary antibody. Plaque forma- 
tion  by  cells  was  equally  inhibited  by  high  dilutions  of the  appropriate 
complementary antibody whether cells were from mice immunized with one, 
the  other,  or  both  antigens.  Thus,  the  absence  of regulation could  not  be 
accounted for by emergence of different idiotypes. Interestingly, sera from mice 
immunized to have high responses to both antigens were relatively ineffective 
in inhibiting plaque formation or suppressing immunization to Pc.  However, 
such sera contained complexes of the complementary antibodies;  apparently 
antibody to  Pc  in  such sera quenches or neutralizes the activity of anti-H8 
antibody.  But  the  formation  of complexes,  at  least  measurable  levels  of 
circulating complexes, must be a result rather than the cause for the absence of 
reciprocal regulation, since regulation was also absent when immunization to 
Pc was manipulated so that responses were too low to result in detectable levels DONALD  A.  ROWLEY,  GARY  W.  MILLER,  AND  INGRID  LORBACH  161 
of circulating antibody to Pc.  It is proposed that simultaneous complementary 
responses may occur in nature to other antigens and antibodies, and that such 
simultaneous responses may cause pathologic changes. 
Received for publication 26 January 1978. 
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